BioSig Technologies, Inc. (BSGM)
| Market Cap | 26.74M |
| Revenue (ttm) | 331,000 |
| Net Income (ttm) | -31.57M |
| Shares Out | 39.61M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,347 |
| Open | 0.720 |
| Previous Close | 0.692 |
| Day's Range | 0.661 - 0.720 |
| 52-Week Range | 0.630 - 4.580 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | 5.10 (+655.6%) |
| Earnings Date | Jul 4, 2022 |
About BSGM
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BSGM stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 655.56% from the latest price.
News
BioSig Announces Pricing of Public Offering of Common Stock
Westport, CT, June 24, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering great...
BioSig Announces Proposed Public Offering of Common Stock
Westport, CT, June 23, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal process...
BioSig Advances its PURE™ System Commercial Launch to Medical Centers Nationwide
Westport, CT, May 26, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering great...
BioSig's PURE EP™ System to be Featured During EPLive 2022
The Company's flagship technology to be featured during a two-day educational conference that draws the world's top cardiac electrophysiology experts The Company's flagship technology to be featured dur...
BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements
Westport, CT, May 11, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering great...
BioSig to Present at Heart Rhythm 2022
Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software Company's conference program to includ...
BioSig to Present at NobleCon18 Capital Markets Conference
Westport, CT, April 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfo...
BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services
The leasing and finance program provides a non-recourse financial solution for PURE EP™ to improve purchase flexibility for U.S. hospitals The leasing and finance program provides a non-recourse financi...
BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer
Seasoned electrophysiology commercial leader joins the Company to expand operating capabilities Seasoned electrophysiology commercial leader joins the Company to expand operating capabilities
BioSig Awarded US Patent Claims for its PURE EP™ Noise-Filtering Technology
Westport, CT, Jan. 26, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfor...
BioSig to Present at the 27th Annual International AF Symposium
PURE EP (TM) System to be highlighted in a Spotlight Session by DJ Lakkireddy, M.D., Kansas City Heart Rhythm Institute at HCA Midwest Health PURE EP (TM) System to be highlighted in a Spotlight Session...
BioSig to Present at the 24th Annual Virtual Needham Growth Conference
BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System. BioSig exits 2021 having completed more than 1800 patient cases with the PURE EP™ System.
BioSig Technologies, Inc. Selects Access Strategy Partners to Accelerate Commercial Sales
Leading healthcare management firm to enhance the Company's market access strategy as it expands the installation base of its signal processing technology for arrhythmia care Leading healthcare manageme...
BioSig Expands Its Clinical Footprint In Florida
The Company's signal processing technology for arrhythmia care is being installed in a leading HCA Healthcare-operated facility in Southeast Florida The Company's signal processing technology for arrhyt...
BioSig to Host Conference Call on December 21, 2021
Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfor...
BioSig to Participate in the Benzinga All Access Event on December 14, 2021
Westport, CT, Dec. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfor...
BioSig Technologies, Inc. Appoints Gray Fleming as Chief Commercial Officer
Seasoned electrophysiology sales executive joins the Company to expand the commercial footprint of its signal processing technology for arrhythmia care Seasoned electrophysiology sales executive joins t...
BioSig to Participate in the The Benchmark Company 10th Annual Discovery Conference
Westport, CT, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfor...
BioSig Initiates Artificial Intelligence Development Program with Technion – Israel Institute of Technology
Company partners with the leading academic institution on research and development of AI-driven methods for atrial fibrillation procedures Company partners with the leading academic institution on resea...
BioSig to Host Live Roundtable Webinar to Discuss Clinical Data Delivered With Its Signal Processing Technology For A...
Discussion led by three industry experts scheduled for November 18, 2021 at 8pm ET Discussion led by three industry experts scheduled for November 18, 2021 at 8pm ET
BioSig Adds To Its Clinical Footprint In Texas
The Company's signal processing technology for arrhythmia care is being installed in a highly ranked hospital in Dallas The Company's signal processing technology for arrhythmia care is being installed ...
BioSig Installs its Signal Processing Technology for Arrhythmia Care at a Leading Hospital in Boston
Latest installation follows a steady rise in patient cases conducted with the PURE EP™ System Latest installation follows a steady rise in patient cases conducted with the PURE EP™ System
BioSig Expands its Installation Base in Texas
Signs a new installation agreement with high-volume center in San Antonio Signs a new installation agreement with high-volume center in San Antonio
BioSig Increases Case Volume Estimates
The Company reports increased adoption and commercial activity of its signal processing technology for arrhythmia care The Company reports increased adoption and commercial activity of its signal proces...
Clinical Data Published in the Journal of Cardiovascular Electrophysiology Could Be Important for This Stock
BioSig Technologies, Inc . (NASDAQ: BSGM) announced that an article titled "Evaluation of a Novel Cardiac Signal Processing System for Electrophysiology Procedures: The PURE EP 2.0 Study" has been publi...